University of Virginia School of Medicine scientists have revealed how mistakes in the final step of cell division can have dire consequences for developing brain cells.

Engage Biologics is developing the Tethosome platform, a non-viral DNA delivery system. ・Engage said its platform addresses major challenges such as immune sensing and efficient cellular delivery.

A new @HopkinsMedicine study of mice reveals that epigenetic marks can be inherited in ways that break the century-long ...

Engage Biologics Inc. (“Engage”), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company (“Lilly”). Engage is ...

May2026– 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation ...

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, ...

Me is partnering with HealthEx to allow users to import their medical records, the company said Tuesday at STAT Breakthrough ...

RNA is the means of translating the genetic code embedded in DNA into proteins, which serve as enzymes, transporters, ...

Eli Lilly (LLY) has purchased preclinical-stage company Engage Biologics in a deal worth as much as $202M in cash. Engage Bio’s Tethosome platform represents a non-viral approach to DNA delivery, ...

Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio. Buoyed by its weight-loss windfall, Eli Lilly is continuing ...

Researchers have identified tiny genetic “switches” that appear to play a surprisingly large role in human language ability.

Acting director Tracy Beth Hoeg, MD, PhD, says she was "fired" ...